The estimated Net Worth of Robert F Apple is at least $15.8 Million dollars as of 17 February 2021. Mr Apple owns over 497,479 units of Antares Pharma Inc stock worth over $12,324,608 and over the last 12 years he sold ATRS stock worth over $2,487,395. In addition, he makes $1,003,646 as CEO and Pres & Director at Antares Pharma Inc.
Sign up
Mr Apple ATRS stock SEC Form 4 insiders trading
Mr has made over 15 trades of the Antares Pharma Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 497,479 units of ATRS stock worth $2,487,395 on 17 February 2021.
The largest trade he's ever made was selling 497,479 units of Antares Pharma Inc stock on 17 February 2021 worth over $2,487,395. On average, Mr trades about 35,147 units every 68 days since 2012. As of 17 February 2021 he still owns at least 2,204,760 units of Antares Pharma Inc stock.
You can see the complete history of Mr Apple stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Robert F. Apple biography
Robert F. Apple is the CEO, Pres & Director at Antares Pharma Inc.
What is the salary of Mr Apple?
As the CEO and Pres & Director of Antares Pharma Inc, the total compensation of Mr Apple at Antares Pharma Inc is $1,003,646. There are no executives at Antares Pharma Inc getting paid more.
How old is Mr Apple?
Mr Apple is 55, he's been the CEO and Pres & Director of Antares Pharma Inc since . There are 3 older and 1 younger executives at Antares Pharma Inc. The oldest executive at Antares Pharma Inc is Dr. Peter Sadowski, 73, who is the Sr. VP of Technology Portfolio & Intellectual Property.
What's Mr Apple's mailing address?
Robert's mailing address filed with the SEC is C/O ANTARES PHARMA, INC., 100 PRINCETON SOUTH, SUITE 300, EWING, NJ, 08628.
Insiders trading at Antares Pharma Inc
Over the last 12 years, insiders at Antares Pharma Inc have traded over $29,755,747 worth of Antares Pharma Inc stock and bought 910,400 units worth $1,278,090 . The most active insiders traders include James E Deerfield Mgmt L.P...., James E Deerfield Mgmt L.P...., and Jacques Gonella. On average, Antares Pharma Inc executives and independent directors trade stock every 28 days with the average trade being worth of $751,296. The most recent stock trade was executed by Anton Gueth on 8 July 2021, trading 100,000 units of ATRS stock currently worth $429,000.
What does Antares Pharma Inc do?
Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), Covis Pharma (Covis), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma's FDA-approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA® (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals.
What does Antares Pharma Inc's logo look like?
Complete history of Mr Apple stock trades at Antares Pharma Inc
Antares Pharma Inc executives and stock owners
Antares Pharma Inc executives and other stock owners filed with the SEC include:
-
Robert F. Apple,
CEO, Pres & Director -
Fred M. Powell,
Exec. VP & CFO -
Peter J. Graham,
Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec. -
Greg Defilippis,
Sr. VP of Device Bus. & Alliances -
Dr. Jonathan S. Jaffe,
Interim EVP, Pharmaceutical R&D and Chief Medical Officer -
Dr. Peter Sadowski,
Sr. VP of Technology Portfolio & Intellectual Property -
Edward Tykot,
Sr. VP of Corp. Bus. Devel. -
Tram Bui,
VP of Corp. Communications & Investor Relations -
Keith Muckenhirn,
Principal Accounting Officer, VP of Fin. & Corp. Controller -
Patrick Madsen,
Sr. VP of Operations -
Anton Gueth,
Director -
Robert P Jr Roche,
Director -
Thomas J Garrity,
Director -
Fred M Powell,
Executive Vice President & CFO -
Leonard S Jacob,
Director -
Marvin Samson,
Director -
James E Fickenscher,
Senior Vice President & CFO -
James E Deerfield Mgmt L.P....,
-
Jacques Gonella,
Director -
Peter J Graham,
See Remarks -
James Patrick Tursi,
EVP, Chief Medical Officer -
Peter Greenleaf,
Director -
Karen L. Smith,
Director -
James E Deerfield Mgmt L.P....,
-
Kaushik J Dave,
Executive Vice President -
Jennifer Evans Stacey,
SVP, General Counsel & Secty -
James E Deerfield Mgmt L.P....,
-
Paul K Wotton,
President and CEO -
Eamonn P Hobbs,
Director -
Peter C Richardson,
See Remarks -
Carmen B Volkart,
Director -
Robert F Apple,
President and CEO